Products
XTampzaER

Xtampza ER is Collegium’s first product utilizing its proprietary DETERx® technology platform, and is designed to provide adequate pain control while maintaining its extended-release drug release profile after being subjected to common methods of abuse and accidental misuse. While abuse of Xtampza ER is still possible, FDA has determined that the product has abuse-deterrent properties. The Xtampza ER label supports alternate administration options, including, sprinkling the capsule contents on soft foods or into a cup, and then directly into the mouth, or through a gastrostomy or nasogastric feeding tube.

Full Prescribing Information and Important Safety Information →





Nucynta ER

Nucynta® ER is the only product approved by the FDA for the treatment of chronic pain and neuropathic pain associated with diabetic peripheral neuropathy. Nucynta® ER is an extended release formulation of tapentadol. The tapentadol molecule has a dual mechanism of action that combines mu-opioid receptor agonism with norepinephrine reuptake inhibition. Tapentadol is a centrally acting synthetic analgesic. The exact mechanism of action is unknown. Although the clinical relevance is unclear, preclinical studies have shown that tapentadol is a mu-opioid receptor agonist and a norepinephrine reuptake inhibitor. Analgesia in animal models is derived from both of these properties.

Full Prescribing Information and Important Safety Information →





Nucynta

Nucynta® is an immediate release formulation of tapentadol indicated for the management of acute pain severe enough to require an opioid analgesic. Tapentadol is a centrally acting synthetic analgesic. The exact mechanism of action is unknown. Although the clinical relevance is unclear, preclinical studies have shown that tapentadol is a mu-opioid receptor agonist and a norepinephrine reuptake inhibitor. Analgesia in animal models is derived from both of these properties.

Full Prescribing Information and Important Safety Information →